exelixis.com (EXEL) - יתרות מזומנים למניה אחת

Exelixis, Inc. (EXEL) possesses significant pricing power due to exclusive patents for the vital drug Cabometyx. Cash per share demonstrates current liquidity, with the metric recorded at 3.69. Cost optimization through the outsourcing of production and clinical trials ensures business resilience regardless of economic cycles, stimulating internal innovation growth.
פילוחי מדדים מקיפים ואנליטיקה עבור Exelixis Inc. (EXEL)

For the biotech giant Exelixis, Inc. (EXEL), which maintains pricing power over targeted cancer therapy, the cash per share metric serves as an indicator of internal capital available for expansion without external borrowing. This figure is calculated by dividing total liquidity by the number of shares, reflecting the size of the financial reserve that ensures business stability and the potential for developing new patents.